Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 332 for “"Checkpoint blockade"”.
-
Elucidating mechanisms of tumour resistance to checkpoint blockade
PD-1 immune checkpoint blockade (ICB) has revolutionized cancer immunotherapy. Successful PD-1 ICB improves anti-tumour responses of cytotoxic tumour infiltrating lymphocytes (TILs), but efficacy is limited in some patients. Blockade of co-inhibitory receptor PD-1 on TILs counteracts negative …
-
New approaches to treating cancer using immune-checkpoint blockade
While immune-checkpoint blockade has truly revolutionised cancer treatment in many aspects, the benefits remain limited to certain tumour types. Furthermore, within those tumours that are likely to improve upon treatment, only a fraction of patients actually respond, which highlights the need for …
-
SILENCING XRN1 ENHANCED THE EFFECT OF IMMUNE CHECKPOINT BLOCKADE THERAPY
Despite the remarkable achievement of immune checkpoint blockade (ICB) therapy, the response rate is relatively low and only a subset of patients can benefit from the treatment. We hypothesize that targeting RNA decay machinery may lead to accumulation of aberrant-RNA, triggering interferon (IFN) …
-
Pulsed photothermal therapy as a precondition for immune checkpoint blockade
… with cancer immunotherapies such as immune checkpoint blockade. Although research has demonstrated that pulsed lasers generate more localized heating than continuous wave (CW) lasers, PTT is traditionally administered by CW lasers, and there is a limited amount of research employing pulsed …
-
Persistent Cancer Cells Alter Interferon Signaling After Immune Checkpoint Blockade
Immune checkpoint blockade (ICB) therapies represent a groundbreaking paradigm in cancer treatment, reshaping clinical approaches. Despite their efficacy, relapse remains a common challenge with poorly understood acquired resistance mechanisms. In this study, leveraging multiple mouse models of ICB …
-
Stromal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in Glioblastoma
… refractory to immunotherapy, including immune checkpoint blockade (ICB). Resistance to ICB is a central issue in GBM and is thought to be primarily driven by tumor-imposed immune dysfunction. Here, however, we identify calmodulin-dependent kinase kinase 2 (CaMKK2) as a novel driver of ICB …
-
Intratumoral Sting Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
… regression can be achieved in patients with checkpoint blockade immunotherapy, yet these responses are rare and are not observed in all tumor types. Castration resistant prostate cancer (CRPC) and pancreatic adenocarcinoma (PDAC) are two common lethal cancers that remain refractory to …
-
A Fc Domain-Conjugated Adenosine 2A Receptor Ligand for Immune Checkpoint Blockade
In light of the recent success of immune checkpoint blockade in cancer treatments, new inhibitory molecules and pathways have been increasingly considered as targets for cancer immunotherapy. The adenosine A2A receptor has long been regarded as an important checkpoint target given its role in …
-
Using Genetically Heterogenous Mice To Identify Regulators Of Immune Checkpoint Blockade Response
Immune Checkpoint Inhibitors (ICI) have dramatically improved patient outcomes in metastatic lung cancer, metastatic melanoma, subtypes of renal cancer and others. However, despite the clinical success, most patients still fail to have a durable response. Understanding what determines response and …
-
Immune Checkpoint Blockade Induces Gut Microbiota Translocation That Augments Extraintestinal Anti-Tumor Immunity
Gut microbiota are critical for effective immune checkpoint blockade therapy (ICT) for cancer. The mechanisms by which gut microbiota augment extraintestinal anti-cancer immune responses, however, are largely unknown. Here, we find that ICT induces the translocation of specific endogenous gut …
-
Enhancing immune checkpoint blockade and cancer immunotherapy via tissue targeting and biomaterial nanoparticles
Immune checkpoint blockade (ICB) has emerged in recent years as one of the most promising new cancer therapies. However, a significant majority of patients receiving these therapies 1) do not respond, 2) experience adverse side effects, or 3) respond initially but relapse. Overcoming these …
-
Tumor Interferon Signaling Initiates And Sustains A Multigenic Resistance Program To Immune Checkpoint Blockade
Therapeutic blockade of the CTLA4 and/or PD1 immune checkpoint pathways has resulted in significant anti-tumor responses in broad variety of cancer types, but resistance is common. Using mouse models of metastatic melanoma and breast cancer in combination with CRISPR/Cas9 to selectively delete …
-
Leveraging Macrophage Immune Checkpoint Blockade To Link Innate And Adaptive Immunity Against Solid Tumors
… control disease progression. Potent immune checkpoints, such as PD-1/PD-L1, CTLA4, and here, CD47-SIRPα restrain immunity in normal regulation to protect healthy ‘self’ cells, yet can become dysregulated in the progression of diseases. Antibody-based blockade of such checkpoints has emerged …
-
Unraveling Host-Gut Microbiota Dialogue and Its Impact On Response to Immune Checkpoint Blockade
… cancer patients is monoclonal antibody immune checkpoint blockade (ICB). ICB removes inhibitory signals of T cell activation which enables tumor-reactive T cells to overcome regulatory mechanisms and mount an effective antitumor response. Despite significant clinical gains in the setting of ICB …
-
Breast Cancer Stem Cell Targeting Nano-Chemotherapy and its Synergistic Effects with Immune Checkpoint Blockade
… amplified by the overexpression of immune checkpoints on cancer cells, primarily CD47 and PD-L1, which enable evasion of macrophage and T cell-mediated immune surveillance. Therefore, innovative strategies targeting both bulk cancer cells and BCSCs, while simultaneously activating the host …
-
Tumor Ripk1 Signaling Regulates Intrinsic And Extrinsic Mechanisms Of Resistance To Immune Checkpoint Blockade Therapy
Immune checkpoint blockade therapy (ICB) can result in impressive clinical responses of multiple cancer types, however most patients fail to respond. Mechanisms of resistance include both tumor-intrinsic evasion of immune mediated killing and tumor-extrinsic features in the immune-microenvironment, …
-
Potentiation of The Immune Checkpoint Blockade Response By Metabolic Modulation Is Predictable Using Molecular Imaging
… immunogenicity and tumor sensitivity to immune checkpoint blockade (ICB) as monitored using molecular imaging. Esomeprazole was found to promote tumor immunogenicity and induce tumor control when used to prime tumors one day before beginning ICB treatment. Using acido-Chemical Exchange …
-
Anti-leukemia immunity is enabled by unmasking cross-reactive antigens with vaccination and checkpoint blockade
… lower leukemic burden. We next assessed whether checkpoint blockade or therapeutic vaccination could improve survival in mice with pre-established leukemia. Consistent with the low mutation load in our leukemia model, we found that checkpoint blockade alone had only modest effects on survival. In …
Page 1 of 17